-
Visiting | Zhou Liqun and Professor Wei Qiang: "Chinese Expert Consensus on Testosterone Management in Prostate Cancer (2021 Edition)"
Time of Update: 2023-01-01
Editor's noteAs one of the common male malignant tumors, prostate cancer has the characteristics of late staging when the disease is diagnosed and the incidence rate has increased rapidly in recent ye
-
Professor Ye Lifu: In the era of group "heroes" fighting for hegemony, how CRPC diagnosis and treatment can achieve another breakthrough
Time of Update: 2023-01-01
"An "Medicine" Leye" is a humanistic case collection project cooperated by Beijing Chen Jumei Public Welfare Foundation and Yimaitong. The series of interviews with urologists will focus on the field
-
SUO 2022 | progress of phase III trial for novel molecular imaging diagnosis of prostate cancer announced
Time of Update: 2023-01-01
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
-
Practice prostate case sharing: homeopathic emergence, abiraterone acetate changes the treatment pattern of patients with metastatic castration-resistant prostate cancer
Time of Update: 2023-01-01
Metastatic prostate cancer seriously affects the survival prognosis of patients, in European and American populations, metastatic prostate cancer accounts for only 5%~6% of new prostate cancer, while
-
PSA deep rapid decline, OS long-term "Ke" period, apatamide + ADT in the treatment of mHSPC showed extraordinary strength in classic cases
Time of Update: 2023-01-01
*For medical professionals onlyThe patient, a man with metastatic hormone-sensitive prostate cancer (mHSPC) with multiple bone metastases, achieved a deep reduction in PSA after 2 months of treatment with apatamide + androgen deprivation therapy (ADT), and the patient's PSA decreased from 216.
-
Optimal Choice for PSA and Testosterone Management in Prostate Cancer Simultaneous management of testosterone and PSA
Time of Update: 2023-01-01
Execution: RudolfThis platform is designed to deliver more medical information to healthcare professionals.
Execution: RudolfThis platform is designed to deliver more medical information to healthcare professionals.
Execution:RudolfRudolfThis platform is designed to deliver more medical information to healthcare professionals.
-
Research Frontiers Say important things three times! The key to preventing and treating prostate cancer is early screening! Early screening! Early screening!
Time of Update: 2023-01-01
Table 1 Annual number of mPC diagnoses and age-standardized incidenceThe results of statistical analysis showed that higher PSA screening rate was associated with lower incidence of mPC after 5 years, with an incidence ratio (IRR) of 0.
In summary, the PSA screening rate of VHA medical institutions was inversely correlated with the subsequent incidence of mPC.
-
Express makes urine cancer tests possible! Benchmark Medical initiates clinical trials for early detection of bladder cancer
Time of Update: 2023-01-01
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Today, Benchmark Medical announced the launch of a registered clinical trial of its bladder cancer early detection product UriFind in the United States, and has completed the enrollment of the first patient, hoping to promote the research and development process of this product to achieve early diagnosis of bladder cancer.
-
2022 SUO Bladder cancer marker new evidence, tumor cell B7-H3 expression levels can be used as predictors of platinum-based adjuvant chemotherapy response
Time of Update: 2023-01-01
In this single-center study, B7-H3 was highly expressed in UC patients receiving adjuvant chemotherapy, which was significantly associated with reductions in RFS and CSS.
In this single-center study, B7-H3 was highly expressed in UC patients receiving adjuvant chemotherapy, which was significantly associated with reductions in RFS and CSS.
-
Research Frontiers Please tell the women around you! Vitamin D helps solve the problem of "urine leakage" during menopause
Time of Update: 2023-01-01
Study designThis was a double-blind, placebo-controlled, randomized controlled trial in which investigators selected and included 60 premenopausal (40-49 years) women with confirmed SUI serum vitamin D levels below 30 ng/mL referred to Kerman University Gynecology Clinic in 2020 to 2021 who received 5000 IU of vitamin D3 supplements or placebo per week for 3 months.
-
2022 CSCO Professor Li Yonghong: Evidence-based evidence is updated, opening a new chapter in the treatment of mHSPC in China
Time of Update: 2023-01-01
Professor Li Yonghong pointed out that one of the focuses of this update is based on the results of the PEACE-1 study, and the CSCO guidelines recommend the triple drug regimen of ADT+ abiraterone + docetaxel as a grade I recommendation for high tumor burden mHSPC.
-
Combination therapy with darolutamide significantly improved the prognosis of patients with metastatic hormone-sensitive prostate cancer
Time of Update: 2023-01-01
On March 24, 2022, the New England Journal of Medicine (NEJM) published the results of the ARASENS trial for darolutamide in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The res
-
"Philippines" Long Vision - Big Coffee Visits Professor Ye Dingwei, Professor Han Bangmin, Professor Gao Xu: PSA & testosterone synchronous monitoring, prostate cancer diagnosis and treatment have been carried out far
Time of Update: 2023-01-01
Yimaitong is honored to invite Professor Ye Dingwei of Fudan University Cancer Hospital, Professor Han Bangmin of the First People's Hospital of Shanghai Jiao Tong University School of Medicine and Professor Gao Xu of Shanghai Changhai Hospital to share with us the current status of prostate cancer diagnosis and treatment and the importance of simultaneous monitoring of PSA and testosterone in androgen deprivation therapy (ADT).
-
Research Frontier Patients with urinary frequency, urgency, and dysuria after indwelling double J tube? Try the combination of Mirabeiron and Solinacin!
Time of Update: 2023-01-01
The incidence of lower urinary tract symptoms (LUTS) at the 1st, 2nd, and 4th weeks of treatment and the scores of health-related quality of life (HRQol) and symptom distress in the Overactive Bladder Questionnaire (OAB-q) were compared between the two groups.
-
2022 CSCO Professor Ye Dingwei: Based on the experience of Fudan tumors, the diagnosis and treatment of prostate cancer needs to be accurately combated and jointly won
Time of Update: 2023-01-01
Vice President of the Asia-Pacific Society of Cryosurgery, etcProfessor Ye Dingwei pointed out that prostate cancer ranks first in the world in the incidence of male tumors and the first in the incidence of urological malignant tumors in China, but the epidemiological data of China and Europe and the United States are different.
-
Metastatic hormone-sensitive prostate cancer: the three-drug regimen is expected to set the new standard
Time of Update: 2023-01-01
Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists has been the standard of care for patients with metastatic hormone-sensitive prostate cance
-
Express is expected to be the first in 20 years! Two pivotal Phase 3 trials of GSK reached the primary endpoint and recruitment was stopped early
Time of Update: 2022-11-15
▎WuXi AppTec content team editorGSK today announced the early suspension of recruitment for two pivotal Phase 3 trials of its investigational drug Gepotidacin, on the recommendation of the Independent
-
Clinical essentials Guidelines for the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome
Time of Update: 2022-11-05
GuideChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common urological andrology disease, its pathogenesis is complex and diverse, treatment options are complex, and the efficacy is uncertain, which brings great trouble to clinical work.
-
A mobile app in the Netherlands has effectively improved urinary incontinence in women
Time of Update: 2022-11-05
One year effectiveness of an app-based treatment for urinary incontinence in comparison to care as usual in Dutch general practice: A pragmatic randomised controlled trial over 12 months.
-
Research frontier CRPC-FS may be an intermediate clinical endpoint in clinical trials in patients with localized prostate cancer
Time of Update: 2022-11-01
Given the significant correlation between CRPC-FS and MFS, CRPC-FS may be a potential intermediate clinical endpoint in early clinical trials in BCR patients receiving ADT after topical therapy, with potential savings of up to approximately 12 months (or more) of follow-up.
